TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Now approved for both acute and chronic HCV in adults and children aged 3 and above
25 women students to receive internship, training, and mentorship in Life Sciences segment
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals
Subscribe To Our Newsletter & Stay Updated
